ROSEN, SKILLED INVESTOR COUNSEL, Encourages DouYu International Holdings Limited Investors with Losses to Secure Counsel Before Important Deadline in the Securities Class Action First Filed by the Firm – DOYU

NEW YORK, June 28, 2023 (GLOBE NEWSWIRE) — WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of the securities of DouYu International Holdings Limited (NASDAQ: DOYU) between April 30, 2021 and May 9, 2023, both dates inclusive (the “Class Period”) of the important August 8, 2023 lead plaintiff deadline in the securities class action first filed by the Firm.

SO WHAT: If you purchased DouYu securities during the Class Period you may be entitled to compensation without payment of any out of pocket fees or costs through a contingency fee arrangement.

WHAT TO DO NEXT: To join the DouYu class action, go to https://rosenlegal.com/submit-form/?case_id=15999 or call Phillip Kim, Esq. toll-free at 866-767-3653 or email pkim@rosenlegal.com or cases@rosenlegal.com for information on the class action. A class action lawsuit has already been filed. If you wish to serve as lead plaintiff, you must move the Court no later than August 8, 2023. A lead plaintiff is a representative party acting on behalf of other class members in directing the litigation.

WHY ROSEN LAW: We encourage investors to select qualified counsel with a track record of success in leadership roles. Often, firms issuing notices do not have comparable experience, resources, or any meaningful peer recognition. Many of these firms do not actually litigate securities class actions, but are merely middlemen that refer clients or partner with law firms that actually litigate the cases. Many of these firms do not actually litigate securities class actions. Be wise in selecting counsel. The Rosen Law Firm represents investors throughout the globe, concentrating its practice in securities class actions and shareholder derivative litigation. Rosen Law Firm has achieved the largest ever securities class action settlement against a Chinese Company. Rosen Law Firm was Ranked No. 1 by ISS Securities Class Action Services for number of securities class action settlements in 2017. The firm has been ranked in the top 4 each year since 2013 and has recovered hundreds of millions of dollars for investors. In 2019 alone the firm secured over $438 million for investors. In 2020, founding partner Laurence Rosen was named by law360 as a Titan of Plaintiffs’ Bar. Many of the firm’s attorneys have been recognized by Lawdragon and Super Lawyers.

DETAILS OF THE CASE: According to the lawsuit, throughout the Class Period, defendants made materially false and/or misleading statements and/or failed to disclose, among other things, that: (1) The Chinese government, due to concerns about issues such as video game and computer addiction, as well as content challenging its authority, could become increasingly aggressive towards DouYu regardless of how effective or sincere its attempts to comply with Chinese law were; (2) this increasingly aggressive posture subjected DouYu to a heightened risk of an investigation and subsequent government enforcement action and ultimately resulted in enforcement action; and (3) as a result, defendants’ statements about its business, operations, and prospects, were materially false and misleading and/or lacked a reasonable basis at all relevant times. When the true details entered the market, the lawsuit claims that investors suffered damages.

To join the DouYu class action, go to https://rosenlegal.com/submit-form/?case_id=15999 or call Phillip Kim, Esq. toll-free at 866-767-3653 or email pkim@rosenlegal.com or cases@rosenlegal.com for information on the class action

No Class Has Been Certified. Until a class is certified, you are not represented by counsel unless you retain one. You may select counsel of your choice. You may also remain an absent class member and do nothing at this point. An investor’s ability to share in any potential future recovery is not dependent upon serving as lead plaintiff.

Follow us for updates on LinkedIn: https://www.linkedin.com/company/the-rosen-law-firm or on Twitter: https://twitter.com/rosen_firm or on Facebook: https://www.facebook.com/rosenlawfirm.

Rosen Law Firm represents investors throughout the globe, concentrating its practice in securities class actions and shareholder derivative litigation. Rosen Law Firm was Ranked No. 1 by ISS Securities Class Action Services for number of securities class action settlements in 2017. The firm has been ranked in the top 4 each year since 2013. Rosen Law Firm has achieved the largest ever securities class action settlement against a Chinese Company. Rosen Law Firm’s attorneys are ranked and recognized by numerous independent and respected sources. Rosen Law Firm has secured hundreds of millions of dollars for investors.

Attorney Advertising. Prior results do not guarantee a similar outcome.

——————————

Contact Information:

Laurence Rosen, Esq.
Phillip Kim, Esq.
The Rosen Law Firm, P.A.
275 Madison Avenue, 40th Floor
New York, NY 10016
Tel: (212) 686-1060
Toll Free: (866) 767-3653
Fax: (212) 202-3827
lrosen@rosenlegal.com
pkim@rosenlegal.com
cases@rosenlegal.com
www.rosenlegal.com

GlobeNewswire Distribution ID 8865549

ROSEN, TRUSTED INVESTOR COUNSEL, Encourages Canopy Growth Corporation Investors to Secure Counsel Before Important Deadline in Securities Class Action – CGC

NEW YORK, June 27, 2023 (GLOBE NEWSWIRE) — WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of securities of Canopy Growth Corporation (NASDAQ: CGC) between May 31, 2022 and May 10, 2023, both dates inclusive (the “Class Period”), of the important July 24, 2023 lead plaintiff deadline.

SO WHAT: If you purchased Canopy Growth securities during the Class Period you may be entitled to compensation without payment of any out of pocket fees or costs through a contingency fee arrangement.

WHAT TO DO NEXT: To join the Canopy Growth class action, go to https://rosenlegal.com/submit-form/?case_id=16092 or call Phillip Kim, Esq. toll-free at 866-767-3653 or email pkim@rosenlegal.com or cases@rosenlegal.com for information on the class action. A class action lawsuit has already been filed. If you wish to serve as lead plaintiff, you must move the Court no later than July 24, 2023. A lead plaintiff is a representative party acting on behalf of other class members in directing the litigation.

WHY ROSEN LAW: We encourage investors to select qualified counsel with a track record of success in leadership roles. Often, firms issuing notices do not have comparable experience, resources or any meaningful peer recognition. Many of these firms do not actually handle securities class actions, but are merely middlemen that refer clients or partner with law firms that actually litigate the cases. Be wise in selecting counsel. The Rosen Law Firm represents investors throughout the globe, concentrating its practice in securities class actions and shareholder derivative litigation. Rosen Law Firm has achieved the largest ever securities class action settlement against a Chinese Company. Rosen Law Firm was Ranked No. 1 by ISS Securities Class Action Services for number of securities class action settlements in 2017. The firm has been ranked in the top 4 each year since 2013 and has recovered hundreds of millions of dollars for investors. In 2019 alone the firm secured over $438 million for investors. In 2020, founding partner Laurence Rosen was named by law360 as a Titan of Plaintiffs’ Bar. Many of the firm’s attorneys have been recognized by Lawdragon and Super Lawyers.

DETAILS OF THE CASE: According to the lawsuit, defendants throughout the Class Period made false and/or misleading statements and/or failed to disclose that: (1) there were material weaknesses in Canopy Growth’s internal controls over accounting and financial reporting; (2) as a result, Canopy Growth improperly booked sales of its BioSteel business unit; (3) as a result, Canopy Growth’s revenue was overstated; and (4) as a result of the foregoing, defendants’ positive statements about Canopy Growth’s business, operations, and prospects were materially misleading and/or lacked a reasonable basis. When the true details entered the market, the lawsuit claims that investors suffered damages.

To join the Canopy Growth class action, go to https://rosenlegal.com/submit-form/?case_id=16092 or call Phillip Kim, Esq. toll-free at 866-767-3653 or email pkim@rosenlegal.com or cases@rosenlegal.com for information on the class action.

No Class Has Been Certified. Until a class is certified, you are not represented by counsel unless you retain one. You may select counsel of your choice. You may also remain an absent class member and do nothing at this point. An investor’s ability to share in any potential future recovery is not dependent upon serving as lead plaintiff.

Follow us for updates on LinkedIn: https://www.linkedin.com/company/the-rosen-law-firm, on Twitter: https://twitter.com/rosen_firm or on Facebook: https://www.facebook.com/rosenlawfirm/.

Attorney Advertising. Prior results do not guarantee a similar outcome.

——————————

Contact Information:

Laurence Rosen, Esq.
Phillip Kim, Esq.
The Rosen Law Firm, P.A.
275 Madison Avenue, 40th Floor
New York, NY 10016
Tel: (212) 686-1060
Toll Free: (866) 767-3653
Fax: (212) 202-3827
lrosen@rosenlegal.com
pkim@rosenlegal.com
cases@rosenlegal.com
www.rosenlegal.com

GlobeNewswire Distribution ID 8865547

Sensegen launches bio-based Exotic Flavors collection

Unveiling at IFT First 2023 in Chicago July 17 – 19

Rancho Santa Margarita, Calif., June 27, 2023 (GLOBE NEWSWIRE) — Sensegen, the pioneering biotechnology-based solution provider in taste, smell, and beauty, has launched its highly anticipated Exotic Flavors collection.

Sensegen has created a range of captivating flavors for food and beverages. The collection features six unique exotic true-to-fruit flavors: lychee, guava, papaya, yuzu, dragon fruit, and violet.

“We are thrilled to introduce the Exotic Flavors collection to the market, representing a significant milestone in our mission to redefine taste and consumer experiences,” said Natasha D’Souza, VP of Flavors and Consumer Experience at Sensegen.

“Our research has revealed that exotic flavors transcend vacation settings and have become a top preference for various occasions and drink preferences. By leveraging our bio-based solutions, we invite food and beverage companies to explore the immense potential of these flavors across different categories and create truly personalized experiences for their consumers,” said D’Souza.

According to Sensegen’s Sensory and Consumer Insights Center, 48% of consumers identified exotics as a top flavor. Consumers are open to more adventurous flavors in social settings or when they feel exploratory. In alcoholic beverages, consumers consider unique, exotic, and natural flavors as the top three desired characteristics.

Sensegen will unveil the Exotic Flavors collection at IFT First in Chicago, July 17-19, 2023, at its creative partner Blue California’s booth S1670. In anticipation of the collection, IFT attendees will be the first to taste food and beverage prototypes made with the flavors and complimentary ingredients from Sensegen’s sugar reduction solutions partner Sweegen.

What to Experience at IFT First 2023
IFT Attendees can expect several exciting prototypes to inspire their products with the Exotic Flavors.
A sneak preview is below.

  • Yuzu-flavored iced tea featuring Sensegen’s yuzu natural flavor with Blue California’s longevity vitamin ergothioneine and Sweegen’s Signature Stevia and taste modulation solutions.
  • Dark chocolate truffles flavored with Sensegen lychee and natural violet flavor. 
  • A better-for-you Guava energy drink made with Sensegen’s guava natural flavor and 50% reduced sugar with Sweegen’s Sweetensify Flavors for taste modulation. Guava has risen 22% YOY in beverages and 5% on restaurant menus.
  • Papaya-flavored refresher featuring Sensegen’s papaya natural flavor. Papaya has increased by 19% on restaurant menus.
  • Dragon fruit-flavored sparkling water flavored with Sensegen’s dragon fruit natural flavor.

This launch results from Sensegen’s relentless pursuit of innovation and commitment to providing consumers with unique taste experiences. The Exotic Flavors collection is supported by the company’s proprietary quantitative research conducted nationally with over 1,500 consumers. This comprehensive study explored the beverage and food choices people make in various situations, the influence of mood on those decisions, and the underlying reasons behind them.

Sensegen’s insights from this research offer invaluable guidance to food and beverage companies seeking to inspire innovation with mood-centric flavors. By understanding that mood, food, and beverage choices can vary significantly among individuals, industry players can use this research to tap into the full potential of their offerings and deliver tailored experiences to their diverse consumer base.

In line with Sensegen’s commitment to sustainability and biotechnology, the Exotic Flavors collection is produced by bioconversion. This approach ensures the highest quality and authenticity while minimizing the environmental impact of flavor production.

About Sensegen
Sensegen™ is the science of good sense. We’ve got nature down to a science.

As a division of Blue California Ingredients, our innovative taste, smell, and beauty creative center is dedicated solely to delivering plant-based, natural, and sustainable solutions. Our diverse team of experts collaborates with advanced bio-techniques and collaborates as a team to provide unique consumer-validated ingredients.

At Sensegen™, we’ve pioneered a way of formulating nature without compromise or harm, providing one-of-a-kind solutions for Taste, Smell, and Beauty.

Attachments

Ana Capretz, Head of PR and Communications
Sensegen
+1.949.635.1991
ana.capretz@sensegen.com

GlobeNewswire Distribution ID 8865558

ROSEN, RECOGNIZED INVESTOR COUNSEL, Encourages Icahn Enterprises L.P. Investors to Secure Counsel Before Important July 10 Deadline in Securities Class Action – IEP

NEW YORK, June 27, 2023 (GLOBE NEWSWIRE) —

WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of securities of Icahn Enterprises L.P. (NASDAQ: IEP) between August 2, 2018 and May 9, 2023, both dates inclusive (the “Class Period”), of the important July 10, 2023 lead plaintiff deadline.

SO WHAT: If you purchased Icahn Enterprises securities during the Class Period you may be entitled to compensation without payment of any out of pocket fees or costs through a contingency fee arrangement.

WHAT TO DO NEXT: To join the Icahn Enterprises class action, go to https://rosenlegal.com/submit-form/?case_id=16028 or call Phillip Kim, Esq. toll-free at 866-767-3653 or email pkim@rosenlegal.com or cases@rosenlegal.com for information on the class action. A class action lawsuit has already been filed. If you wish to serve as lead plaintiff, you must move the Court no later than July 10, 2023. A lead plaintiff is a representative party acting on behalf of other class members in directing the litigation.

WHY ROSEN LAW: We encourage investors to select qualified counsel with a track record of success in leadership roles. Often, firms issuing notices do not have comparable experience, resources or any meaningful peer recognition. Many of these firms do not actually handle securities class actions, but are merely middlemen that refer clients or partner with law firms that actually litigate the cases. Be wise in selecting counsel. The Rosen Law Firm represents investors throughout the globe, concentrating its practice in securities class actions and shareholder derivative litigation. Rosen Law Firm has achieved the largest ever securities class action settlement against a Chinese Company. Rosen Law Firm was Ranked No. 1 by ISS Securities Class Action Services for number of securities class action settlements in 2017. The firm has been ranked in the top 4 each year since 2013 and has recovered hundreds of millions of dollars for investors. In 2019 alone the firm secured over $438 million for investors. In 2020, founding partner Laurence Rosen was named by law360 as a Titan of Plaintiffs’ Bar. Many of the firm’s attorneys have been recognized by Lawdragon and Super Lawyers.

DETAILS OF THE CASE: According to the lawsuit, throughout the Class Period, defendants made materially false and/or misleading statements and/or failed to disclose that: (1) Icahn Enterprises was inflating its net asset value; (2) Icahn Enterprises was using money taken in from new investors to pay out dividends to old investors; (3) as a result, Icahn Enterprises would become the subject of criminal and/or regulatory scrutiny; and (4) as a result of the foregoing, defendant’s positive statements about the Company’s business, operations, and prospects were materially misleading and/or lacked a reasonable basis. When the true details entered the market, the lawsuit claims that investors suffered damages.

To join the Icahn Enterprises class action, go to https://rosenlegal.com/submit-form/?case_id=16028 or call Phillip Kim, Esq. toll-free at 866-767-3653 or email pkim@rosenlegal.com or cases@rosenlegal.com for information on the class action.

No Class Has Been Certified. Until a class is certified, you are not represented by counsel unless you retain one. You may select counsel of your choice. You may also remain an absent class member and do nothing at this point. An investor’s ability to share in any potential future recovery is not dependent upon serving as lead plaintiff.

Follow us for updates on LinkedIn: https://www.linkedin.com/company/the-rosen-law-firm, on Twitter: https://twitter.com/rosen_firm or on Facebook: https://www.facebook.com/rosenlawfirm/.

Attorney Advertising. Prior results do not guarantee a similar outcome.

——————————

Contact Information:

Laurence Rosen, Esq.
Phillip Kim, Esq.
The Rosen Law Firm, P.A.
275 Madison Avenue, 40th Floor
New York, NY 10016
Tel: (212) 686-1060
Toll Free: (866) 767-3653
Fax: (212) 202-3827
lrosen@rosenlegal.com
pkim@rosenlegal.com
cases@rosenlegal.com
www.rosenlegal.com

GlobeNewswire Distribution ID 8865487

Zoom brings together in-office and remote employees with the launch of Intelligent Director for Zoom Rooms

AI-powered Intelligent Director enhances connection and optimizes the conference room experience for hybrid work, using multiple cameras to give every participant their own space in Zoom Meetings

SAN JOSE, Calif., June 27, 2023 (GLOBE NEWSWIRE) — Today Zoom Video Communications, Inc. (NASDAQ: ZM) announced the launch of the award-winning Intelligent Director for Zoom Rooms. For hybrid meetings with a Zoom Room, Intelligent Director uses AI and multiple cameras to provide the best image and angle of participants in the room so remote participants can see each person clearly, even in large conference rooms.

“As more people return to the office, it’s no longer enough to deliver the best remote worker experience; every business needs a solution to deliver the best hybrid meeting experience,” said Smita Hashim, chief product officer at Zoom. “Even with some employees in the office, oftentimes other team members are dispersed, so meeting equity and inclusion become more important than ever. Intelligent Director is the solution that can bring employees together, regardless of location, so they can truly connect face-to-face.”

Intelligent Director is specifically designed for medium- to larger-sized rooms and helps avoid the “bowling alley effect.” Intelligent Director can individually frame up to 16 participants in a Zoom Room using multiple cameras, choosing the best video stream via a Zoom-designed AI, and send that stream to the gallery view of the Zoom Meeting.

An evolution of Zoom’s Smart Gallery feature, which uses a single camera and AI to give each person in a small to medium-sized room their own space in a Zoom Meeting, Intelligent Director takes this same technology to the next level for larger conference rooms.

For bigger meeting spaces, it is easier to be hidden by others when only using a single camera, so Intelligent Director’s multi-camera configuration and use of video AI technology provide meeting equity to everyone in the room, selecting the best view of each individual, even if they move around or turn their heads. Remote participants can now have face-to-face conversations with each Zoom Rooms participant, allowing in-room participants to be seen and heard.

Intelligent Director is made possible through the support of Zoom’s hardware partner ecosystem. Manufacturers, including Apple, AVer, Dell, HP | Poly, Intel, Logitech, and Yealink have supported Zoom with the computer, controller, and camera solutions necessary to produce this major advancement.

About Zoom
Zoom is an all-in-one intelligent collaboration platform that makes connecting easier, more immersive, and more dynamic for businesses and individuals. Zoom technology puts people at the center, enabling meaningful connections, facilitating modern collaboration, and driving human innovation through solutions like team chat, phone, meetings, omnichannel cloud contact center, smart recordings, whiteboard, and more, in one offering. Founded in 2011, Zoom is publicly traded (NASDAQ:ZM) and headquartered in San Jose, California. Get more info at zoom.com.

Zoom Public Relations
Lacretia Taylor
press@zoom.us

GlobeNewswire Distribution ID 8865322

Medela Concludes Global Breastfeeding Symposium with Key Takeaways in Lactation Science to Inform Clinical Practice

Leading Breast Pump Brand Hosts Global Event to Advance Breastfeeding Research and Understand Current Hospital-Based Practices, Sharing Research Findings Free of Charge

Switzerland, Baar, June 27, 2023 (GLOBE NEWSWIRE) — Medela, the brand trusted by millions of moms*, concluded its 16th Global Breastfeeding and Lactation Symposium, focused on advancing lactation science to improve care. This three-part world tour was held in three locations, kicking off in Chicago, Illinois in April, followed by Beijing, China in May, and concluding in Munich, Germany in June. All three events welcomed more than 2,600 healthcare professionals in maternal and infant care to learn about the latest research findings and key insights from globally and regionally renowned experts in human milk and lactation. Delivering on Medela’s commitment of turning science into care, speaker presentations from the series will be available free of charge for virtual access through Medela University from next week.

“By bringing together top minds in lactation science from around the world, we are able to further our shared goal of improving maternal and infant health outcomes,” said Annette Brüls, CEO of  Medela worldwide. “We know that conducting the research is only half of a much larger picture, which is why our Global Symposium is committed to creating a dynamic learning opportunity to transfer this knowledge from the experts in science and research to the leaders in healthcare settings around the world. We are bridging the gap between research and practice, making it accessible, free of charge, to the people who use and need it, with the sole intention of nurturing health for generations.”

The global event featured presentations and discussions from experts, including:

PROF. LARS BODE (USA) | Lactation as a biological system: The dynamics of human milk composition

“Human milk and lactation do not stand in isolation; they are part of a dynamic biological system that is embedded in socioeconomic, cultural, behavioral, and environmental contexts,” explains Professor Bode, Ph.D., at the University of California San Diego. “As a scientist, it was exciting to participate in Medela’s Breastfeeding & Lactation Symposia because the events connect the science with the clinical application of human milk and lactation, which together is a major driver to advance the field with maximum impact on infant health and development.”

PROF. DONNA GEDDES (AU) | Lactation as a biological system: The importance of dose

“As we seek to understand how human milk composition impacts the health of our next generation, we often default to analyzing concentrations of milk components. Yet when we measure the dose the baby receives, a new world opens up with the promise of innovative ways to improve the health of our children,” says Professor Geddes from the University of Western Australia. “I appreciate the opportunity to share my scientific findings at this stellar conference, but I find the interaction with the participants invaluable, as they come from all disciplines essential to improving breastfeeding and breast milk delivery for all lactating women and their babies.”

DR. REBECCA HOBAN (CA) | Initiation of lactation: Prophylactic lactation support as standard of care for mothers of NICU infants

“Although we know that mother’s milk is literally lifesaving for preterm infants in the NICU, many mothers struggle to make enough milk for their babies, limiting their infant’s lifelong milk dose and it is my passion to optimize lactation for these vulnerable families,” shares Dr. Hoban, staff neonatologist and Director of Breastfeeding Medicine at The Hospital for Sick Children in Toronto. “Medela’s Symposium brings new lactation evidence to clinician leaders who will translate the science to the bedside for families around the world. It’s a great way to ‘spread the word’ about the latest findings in breastfeeding research!”

PROF. DIANE SPATZ (USA) | A call to action: Improving human milk and breastfeeding outcomes by prioritizing effective initiation of lactation

“There is a critical window for the establishment of a milk supply and, we as advocates and clinicians have an obligation to families to teach them the science of human milk and the physiology of lactation,” explains Professor Diane Spatz, who also serves as chairperson for Medela’s Scientific and Clinical Advisory Board in the Americas. Prof. Spatz presented a call to action about the need for prioritizing effective initiation of lactation in order to improve exclusivity and duration of breastfeeding. Prof. Spatz is a Professor of Perinatal Nursing at the University of Pennsylvania School of Nursing sharing a joint appointment at Children’s Hospital of Philadelphia.

Held as a hybrid event in Beijing on May 13-14, the China Symposium focused on providing a platform for like-minded breastfeeding professionals to share ideas, experiences and best practices. In partnership with the China Maternity and Child Health Association, the event marked a shared commitment to educating individuals on the benefits of human milk, while strengthening the collective efforts to foster a supportive environment for breastfeeding in China.

PROF. CAO YUN (CHINA) | The impact of human milk feeding on the outcomes of NICU premature infants based on clinical research in China

”As an experienced NICU physician, I have been promoting human milk feeding since I learned of its benefits for NICU infants. I am pleased to see so many obstetrics, pediatrics, and nursing experts gathered here. The promotion of breastfeeding cannot be achieved without the cooperation of various departments and multi-disciplinary teams.” says Prof. Cao Yun from Fudan University Children Hospital. “It is great that Medela organizes such an informative symposium that allows us to unite to promote breastfeeding in China.”

PROF. YU HONG (CHINA) Quality improvement study on breastfeeding in mother-infant-separation dyads after standardized interventions

“I was very excited to participate in this grand event organized by Medela and learned about global cutting-edge research,” says Prof. Yu Hong from Southeast University Zhongda Hospital. “I led a multiple-center quality improvement study in Jiangsu Province, and our objective is to support lactation and improve the dose of own mother’s milk feeding through the evidence-based interventions.”

PROF. FENG QI (CHINA) Clinical study on promoting breastfeeding of premature infants in China

“Breastfeeding is not only a mother’s business, but also depends on family and social support,” says Prof. Feng Qi from Peking University First Hospital. “At present, the government has issued documents to support breastfeeding, and we also have the consensus from professional groups. As more and more hospitals are paying increasing attention to breastfeeding, we need to proactively adopt best clinical practices to improve breastfeeding in the NICU.”

DR. YUKI TAKAHASHI (JAPAN) | Effect of epidural analgesia on infant sucking and opportunities for improvement to achieve the standard of care for infants

“Intrapartum interventions such as epidural analgesia or induction of labor can influence skin-to-skin contact and rooting/suckling behavior, not only right after, but up to two days after birth,” says Dr. Yuki Takahashi from Nagoya University Japan. “And the important thing is to prioritize breastfeeding support resources to provide behaviorally appropriate and individualized care during this critical period.”

On June 23-24, Medela hosted the European Edition of their world tour in Munich, Germany, and welcomed two internationally renowned British speakers who shared their insights for improving lactation support in the neonatal intensive care unit. On day two of the symposium the healthcare experts on-site took these findings into curated workshops with the goal of translating them into clinical practice.

PROF. NEENA MODI (UK) | Perspectives: Prioritizing own mother´s milk in the neonatal unit – need for standardized metrics that capture lactation and infant feeding

“Prioritizing the provision of own mother’s milk (OMM) is a crucial step in neonatal care and thorough, high-quality data on lactation and infant feeding are fundamental in assessing the success of OMM provision and understanding the extent to which infants leave the neonatal unit breastfeeding,” asserts Professor Neena Modi of the Imperial College London, who also serves as President-elect of the European Association of Perinatal Medicine. Prof. Modi underscored that by implementing standardized information recording in neonatal units, we can develop universally accepted quality indicators, improve care, and drive research for better breastfeeding outcomes.

DR. SARAH BATES (UK) | Spotlight: Improving survival & outcomes for preterm infants through optimizing early maternal breast milk – a national Quality Improvement toolkit from BAPM

“Optimizing own mother’s milk (OMM) is crucial for the long-term health of preterm infants,” explained Dr. Sarah Bates, Consultant Pediatrician and Neonatologist at the Great Western Hospital in Swindon. In her talk Dr. Bates shed light on the innovative national toolkits created by the British Association of Perinatal Medicine, demonstrating its utility in optimizing OMM for preterm infants from initiation of lactation to post-discharge. Her session, infused with success stories and insightful parental views, showcased how this initiative can positively reshape the health trajectories of preterm infants nationwide.

Turning science into care

Presentations from speakers will be available free of charge for virtual access through Medela University, an online professional education platform for lactation science offering continuing education units (CEUs).

In addition, Medela will host a series of educational webinars in the US and Europe to translate existing research findings into clinical practice and share important conclusions and expert recommendations. While the US webinars will focus primarily on disparities in breastfeeding and resources for clinicians to assess their own implicit bias and alter clinical practice to better support Black women who breastfeed, the European webinars will focus on improving lactation science and improving care in neonatal units.

Learn more about the Global Breastfeeding and Lactation Symposium at medela.com/symposium.

Media resources, including language versions of the press releases and visual assets are available for download at medela.com/symposium-media.

About Medela

Through advancing research, observing natural behavior, and listening to our customers, Medela turns science into care while nurturing health for generations. Medela supports millions of moms, babies, patients, and healthcare professionals in more than 100 countries all over the world. As the healthcare choice for more than 6 million hospitals and homes across the globe, Medela provides leading research-based breast milk feeding and baby products, healthcare solutions for hospitals, and clinical education. Medela is dedicated to building better health outcomes, simplifying and improving life, and developing breakthroughs that help moms, babies and patients live their life to the fullest. For more information, visit www.medela.com.

* Medela global sales, 2022

Attachments

Media Office
Medela
Media.Inquiries@medela.com

GlobeNewswire Distribution ID 8865260